| scholarly article | Q13442814 |
| P50 | author | William Pao | Q28025149 |
| Mark G Kris | Q37621431 | ||
| Camelia S Sima | Q114291522 | ||
| P2093 | author name string | Vincent A Miller | |
| Melissa L Johnson | |||
| Michelle S Ginsberg | |||
| Christopher G Azzoli | |||
| Naiyer A Rizvi | |||
| Greg J Riely | |||
| P2860 | cites work | MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib | Q24646295 |
| Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain | Q24794765 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| Mechanism of biological synergy between cellular Src and epidermal growth factor receptor | Q30454480 | ||
| Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia | Q33379934 | ||
| Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer | Q34281221 | ||
| Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer | Q34578584 | ||
| Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas | Q35789960 | ||
| Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial | Q36097426 | ||
| Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification | Q39791455 | ||
| Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival | Q40272854 | ||
| Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer | Q42780600 | ||
| Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors | Q43182188 | ||
| Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. | Q53465653 | ||
| P433 | issue | 6 | |
| P921 | main subject | erlotinib | Q418369 |
| dasatinib | Q419940 | ||
| dasatinib monohydrate | Q27139135 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 1128-1131 | |
| P577 | publication date | 2011-06-01 | |
| P1433 | published in | Journal of Thoracic Oncology | Q2448056 |
| P1476 | title | Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib | |
| P478 | volume | 6 |
| Q46752829 | AC-93253 iodide, a novel Src inhibitor, suppresses NSCLC progression by modulating multiple Src-related signaling pathways |
| Q34694358 | Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation |
| Q37623870 | Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss |
| Q35742415 | Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation |
| Q34263959 | Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial |
| Q36673751 | Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. |
| Q42315652 | Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. |
| Q42206973 | Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion |
| Q50056486 | Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis |
| Q91645953 | Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML |
| Q34135471 | Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations |
| Q52652986 | EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation. |
| Q48267724 | Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas. |
| Q37381182 | IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells |
| Q36544565 | Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells |
| Q28481644 | In silico investigation of potential SRC kinase ligands from traditional Chinese medicine |
| Q37696232 | LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients. |
| Q34432733 | Lung injury and lung cancer caused by cigarette smoke-induced oxidative stress: Molecular mechanisms and therapeutic opportunities involving the ceramide-generating machinery and epidermal growth factor receptor. |
| Q39210492 | Molecular dissection of AKT activation in lung cancer cell lines |
| Q55401599 | Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer. |
| Q35196345 | New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer |
| Q36939668 | Non-small-cell lung cancer cells combat epidermal growth factor receptor tyrosine kinase inhibition through immediate adhesion-related responses |
| Q92422523 | Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance |
| Q48022638 | Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer |
| Q39297048 | Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck |
| Q35659675 | Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells |
| Q36413425 | Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways |
| Q38833666 | SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer |
| Q92715575 | SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC |
| Q37996268 | Signalling pathways passing Src in pancreatic endocrine tumours: relevance for possible combined targeted therapies. |
| Q38815335 | Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma |
| Q30278774 | Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status |
| Q38748552 | Synthesis and biological evaluation of novel dasatinib analogues as potent DDR1 and DDR2 kinase inhibitors |
| Q33754114 | The new concepts on overcoming drug resistance in lung cancer |
| Q33725976 | The quest to overcome resistance to EGFR-targeted therapies in cancer |
| Q38132282 | The role of afatinib in the management of non-small cell lung carcinoma |
| Q38258948 | Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors |
| Q34260686 | Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. |
| Q28542671 | Transforming growth factor β signaling overcomes dasatinib resistance in lung cancer |
| Q37241709 | Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung |
| Q33992604 | Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer |
| Q47139623 | YAP1 is essential for tumor growth and is a potential therapeutic target for EGFR-dependent lung adenocarcinomas |
| Q55634316 | YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. |
Search more.